This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page  |  Report Abuse  |  Sign In  |  Register
Antisense Therapy and Lp(a)
Share |

Proposed Phase II Study on Antisense Therapy Targeting Apolipoprotein(a) (right click on the image below to download to your desktop)

 

CLINICAL TRIAL

POSITIVE CLINICAL DATA FROM Lp(a) LOWERING DRUG ISIS-APO(a)Rx PUBLISHED IN THE LANCET

The paper titled "Antisense therapy targeting apolipoprotein(a): a randomized, double-blind, placebo-controlled phase 1 study" (Tsimikas et al, The Lancet 2015 : published online today), reported data from the Phase 1 study evaluating single and multiple ascending doses of ISIS-APO(a)Rx in healthy volunteers with elevated Lp(a) concentrations of 25 nmol/L (100 mg/L) or more. Results of this study demonstrated potent, dose-dependent, selective reductions of plasma Lp(a) up to 89% (mean reduction up to 78%) in patients treated with ISIS-APO(a)Rx.

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Lancet. 2015 Oct 10;386(10002):1472-83. doi: 10.1016/S0140-6736(15)61252-1. Epub 2015 Jul 22.

Tsimikas S1, Viney NJ2, Hughes SG2, Singleton W2, Graham MJ2, Baker BF2, Burkey JL2, Yang Q2, Marcovina SM3, Geary RS2, Crooke RM2, Witztum JL4.

ISIS-APO(a)Rx results in potent, dose-dependent, selective reductions of plasma Lp(a). The safety and tolerability support continued clinical development of ISIS-APO(a)Rx as a potential therapeutic drug to reduce the risk of cardiovascular disease and calcific aortic valve stenosis in patients with elevated Lp(a) concentration.

 

  

 

Community Search
Sign In
Login with LinkedIn
OR


Latest News
 
809 Laurel Street #460
San Carlos, CA 94070
650/995.3242